84 related articles for article (PubMed ID: 2348875)
21. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
[TBL] [Abstract][Full Text] [Related]
22. Erythropoietin and chronic renal failure.
Drüeke T; Zins B; Naret C; Casadevall N; Goureau Y; Bererhi L; Zingraff J; Delons S; Kreis H; Varet B
Nouv Rev Fr Hematol (1978); 1989; 31(2):97-8. PubMed ID: 2771635
[No Abstract] [Full Text] [Related]
23. Response to recombinant human erythropoietin (rHu-Epo) in a patient with chronic renal failure and myelomonocytic leukaemia.
Salvati F; Liani M; Bonomini M
Nephrol Dial Transplant; 2001 Jan; 16(1):191-2. PubMed ID: 11209030
[No Abstract] [Full Text] [Related]
24. Does correction of anemia with recombinant human erythropoietin accelerate the progression of renal insufficiency?
Lim VS
Semin Nephrol; 1990 Mar; 10(2 Suppl 1):26-7. PubMed ID: 2356366
[No Abstract] [Full Text] [Related]
25. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
[TBL] [Abstract][Full Text] [Related]
26. [The role of erythropoietin].
Godin M
Soins; 2004 Sep; (688 Suppl):5. PubMed ID: 15526820
[No Abstract] [Full Text] [Related]
27. Treatment of anaemia in chronic renal failure.
Beer J
Nurs Times; 1988 Nov 23-29; 84(47):55-7. PubMed ID: 3211795
[No Abstract] [Full Text] [Related]
28. Management of the anaemia of chronic renal failure with recombinant erythropoietin.
Adamson JW; Eschbach JW
Q J Med; 1989 Dec; 73(272):1093-101. PubMed ID: 2694210
[No Abstract] [Full Text] [Related]
29. [Gaining time in the treatment of anemia of patients with kidney failure].
Rigal F
Soins; 2008 Nov; (730):33-4. PubMed ID: 19068911
[No Abstract] [Full Text] [Related]
30. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
[TBL] [Abstract][Full Text] [Related]
31. Influence of erythropoietin treatment on 2,3-bisphosphoglycerate and O2-affinity of red blood cells in children with renal anemia.
Rapoport I; Engelhardt I; Drung I; Holzhütter H; Schmidt G
Biomed Biochim Acta; 1990; 49(2-3):S280-3. PubMed ID: 2386518
[TBL] [Abstract][Full Text] [Related]
32. [Hemoglobin target for chronic kidney disease patients?].
Drüeke TB
Nephrol Ther; 2007 Oct; 3(6):369-71. PubMed ID: 17919639
[No Abstract] [Full Text] [Related]
33. Erythropoietin for anemia.
Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
[No Abstract] [Full Text] [Related]
34. r-HuEPO treatment of anemia associated with multiple myeloma and ESRD.
Van der Niepen P; Sennesael J; Verbeelen D
Clin Nephrol; 1993 Feb; 39(2):113. PubMed ID: 8448915
[No Abstract] [Full Text] [Related]
35. Erythropoietin: mechanisms of action and indications for treatment.
Vreugdenhil G; Frenken LA; Koene RA
Neth J Med; 1993 Jun; 42(5-6):187-202. PubMed ID: 8377877
[TBL] [Abstract][Full Text] [Related]
36. Effects of erythropoietin on glucose tolerance in hemodialysis patients.
Chagnac A; Weinstein T; Zevin D; Korzets A; Hirsh J; Gafter U; Levi J
Clin Nephrol; 1994 Dec; 42(6):398-400. PubMed ID: 7882604
[TBL] [Abstract][Full Text] [Related]
37. The end stage renal disease program.
Goodkin DA
N Engl J Med; 1993 Jul; 329(2):140; author reply 140-1. PubMed ID: 8510703
[No Abstract] [Full Text] [Related]
38. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
Hussein MM; Mooij JM; Roujouleh H
Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
[No Abstract] [Full Text] [Related]
39. [Evolution of medical practice in the care of anemia amd the use of erythropoietin in chronic renal insufficiency hemodialysis in the past six years].
Canaud B; Richard A; Fagnani F; Moreau-Defarges T; Guillon P
Nephrologie; 2002; 23(3):123-30. PubMed ID: 12087809
[TBL] [Abstract][Full Text] [Related]
40. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
Verbeelen D; Hauglustaine D; Sennesael J
Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
